Repligen Corporation Stock News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Five stocks indistinguishable from magic and five stocks with a tailwind blow.

Five stocks indistinguishable from magic and five stocks with a tailwind blow.

Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy?

These companies bring different strengths and opportunities to a stock portfolio.

Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.

Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen I

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Yesterday, Catalent Inc (NYSE: CTLT) announced to acquire Metrics Contract Services for $475 million. Keybanc notes that the deal strengthens CTLT's oral delivery portfolio and targets rapidly gro

The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.

The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.